1. Structural Biology and Molecular Biophysics
Download icon

Small-Molecule Inhibitors: Disrupting enzyme fluidity

  1. Ganesh Srinivasan Anand  Is a corresponding author
  1. Department of Chemistry and Huck Institute of Life Sciences, Pennsylvania State University, United States
Insight
  • Cited 0
  • Views 599
  • Annotations
Cite this article as: eLife 2021;10:e65221 doi: 10.7554/eLife.65221

Abstract

A combination of X-ray crystallography, NMR, and mass spectrometry has revealed how diverse small-molecule inhibitors bind Bruton’s tyrosine kinase and alter the conformation of this enzyme.

Main text

The switching of enzymes between active and inactive states, a process known as enzyme regulation, is crucial in cell biology, and the breakdown of the process has been implicated in many diseases. A number of small-molecule inhibitors work by blocking enzyme function, but efforts to evaluate the efficacy of such inhibitors have been hampered by the lack of a detailed understanding of how they work. For example, some small-molecule inhibitors work by making localized changes to the shape of the enzyme at the site where they bind, whereas others work by inducing changes in another part of the enzyme, a phenomenon known as allostery.

A clearer picture of allostery requires detailed knowledge of enzyme function and the underlying protein dynamics (Henzler-Wildman and Kern, 2007). Now, in eLife, Amy Andreotti (Iowa State University), Thomas Wales (Northeastern University) and colleagues – Raji Joseph, Neha Amatya, Bruce Fulton and John Engen – report on the effects of five different small-molecule inhibitors on an enzyme called Bruton’s tyrosine kinase (BTK; Joseph et al., 2020).

BTK is a kinase that regulates the immune responses of B- and T-cells, and blocking its activity can help suppress inflammatory responses and treat lymphomas and leukemias (Kim, 2019). High-resolution snapshots of the active and inactive states of BTK have been previously obtained using X-ray crystallography (Marcotte et al., 2010; Kuglstatter et al., 2011; Xing and Huang, 2014). Similar to other kinases, an important feature in BTK is a switch called a ‘Glu-Lys switch’ (Taylor et al., 1993). When the critical glutamate (Glu) in the switch is positioned close to a specific lysine (Lys) in the catalytic site, the enzyme is more active. When the enzyme is inactive, it adopts a different shape where the same glutamate is further from the lysine.

While X-ray crystallography can provide information on the active and inactive conformations of enzymes at high resolution, additional techniques are needed to understand how enzymes and small-molecule inhibitors interact in solution, so Joseph et al. combined X-ray crystallography with nuclear magnetic resonance (NMR) and amide hydrogen/deuterium exchange mass spectrometry (HDXMS). NMR provides a global overview of conformation, including the transitions between the active and inactive state, while HDXMS localizes conformational changes at a peptide level.

The experiments revealed that BTK exists in an ensemble of conformations, encompassing the inactive and active states of the enzyme (Figure 1). Joseph et al. then explored how five different small-molecule inhibitors (ibrutinib, dasatinib, GDC-0853, CGI1746 and CC-292) interacted with BTK, and found that each inhibitor resulted in varying ratios of inactive and active conformations. These results establish that BTK changes the likelihood of being in a specific conformation within its ensemble, rather than operating as a discrete on/off switch, which is consistent with the idea that proteins exist in several conformations of varying activity (Onuchic and Wolynes, 2004). This work also supports the view that small-molecule inhibitors may favor certain conformations in an ensemble over others (Boehr et al., 2009; Kar et al., 2010). Joseph et al. also examined a mutation in BTK that confers B-cells with resistance to one of the inhibitors: the cancer drug ibrutinib. They found that this mutation disrupts the inactive conformation of BTK, making the enzyme more active and leading to more aggressive lymphomas that can evade the drug.

Active and inactive forms of the enzyme BTK.

(A) Top: In solution BTK populates an ensemble of inactive (left), intermediate (middle) and active (right) conformations. These schematics show the regulatory domain (red), the catalytic domain (blue or green) and activation loop (red or yellow). Activation involves the regulatory domain moving away from the catalytic domain, and the activation loop moving away from the Glu-Lys switch (not shown) in the catalytic domain. Bottom: Structure of the catalytic domain in the inactive (blue, left) and active (green, right) conformations showing the Glu-Lys switch turned away in the inactive state and positionally close together in the active states (Marcotte et al., 2010). These structures of inactive (PDB ID: 3GEN) and active (PDB ID: 3K54) BTK were rendered using the PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC. (B) The effect of a small-molecule inhibitor on an enzyme can be visualized in terms of the way it changes the free energy of an ensemble of interchangeable conformational states of the enzyme. In the absence of the small-molecule inhibitors, the free energy (vertical axis) is different for each of the individual conformations (horizontal axis); the lower the free energy, the more likely the enzyme is likely to exist in that conformation. In this example, small-molecule inhibitor 1 (blue) lowers the free energy to the right of the graph, favoring these specific conformations, whereas small-molecule inhibitor 2 (green) lowers the free energy to the left of the graph, favoring those specific conformations. Mutations in the enzyme can also change the free energy to favor certain conformations. Knowing how different small molecules influence the free energy of the enzyme could help develop new small-molecule inhibitors.

This work underscores the limitations of using structural snapshots from X-ray crystallography or cryo-electron microscopy alone to map small-molecule interaction sites, or to describe allosteric effects. It also highlights how combining NMR and HDXMS with static structural data will lead to more complete descriptions of drug-enzyme interactions. More generally, combining structural, dynamic and computational approaches will help researchers to design inhibitor drugs that are not rendered ineffective by disease-resistant mutations.

References

Article and author information

Author details

  1. Ganesh Srinivasan Anand

    Ganesh Srinivasan Anand is at the Department of Chemistry and Huck Institute of Life Sciences, Pennsylvania State University, University Park, United States

    For correspondence
    gsa5089@psu.edu
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8995-3067

Publication history

  1. Version of Record published: January 25, 2021 (version 1)

Copyright

© 2021, Anand

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 599
    Page views
  • 56
    Downloads
  • 0
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Download citations (links to download the citations from this article in formats compatible with various reference manager tools)

Open citations (links to open the citations from this article in various online reference manager services)

Further reading

    1. Chromosomes and Gene Expression
    2. Structural Biology and Molecular Biophysics
    Luka Bacic et al.
    Research Article Updated

    The chromatin remodeler ALC1 is recruited to and activated by DNA damage-induced poly(ADP-ribose) (PAR) chains deposited by PARP1/PARP2/HPF1 upon detection of DNA lesions. ALC1 has emerged as a candidate drug target for cancer therapy as its loss confers synthetic lethality in homologous recombination-deficient cells. However, structure-based drug design and molecular analysis of ALC1 have been hindered by the requirement for PARylation and the highly heterogeneous nature of this post-translational modification. Here, we reconstituted an ALC1 and PARylated nucleosome complex modified in vitro using PARP2 and HPF1. This complex was amenable to cryo-EM structure determination without cross-linking, which enabled visualization of several intermediate states of ALC1 from the recognition of the PARylated nucleosome to the tight binding and activation of the remodeler. Functional biochemical assays with PARylated nucleosomes highlight the importance of nucleosomal epitopes for productive remodeling and suggest that ALC1 preferentially slides nucleosomes away from DNA breaks.

    1. Microbiology and Infectious Disease
    2. Structural Biology and Molecular Biophysics
    Gukui Chen et al.
    Research Article Updated

    Cyclic-di-guanosine monophosphate (c-di-GMP) is an important effector associated with acute-chronic infection transition in Pseudomonas aeruginosa. Previously, we reported a signaling network SiaABCD, which regulates biofilm formation by modulating c-di-GMP level. However, the mechanism for SiaD activation by SiaC remains elusive. Here we determine the crystal structure of SiaC-SiaD-GpCpp complex and revealed a unique mirror symmetric conformation: two SiaD form a dimer with long stalk domains, while four SiaC bind to the conserved motifs on the stalks of SiaD and stabilize the conformation for further enzymatic catalysis. Furthermore, SiaD alone exhibits an inactive pentamer conformation in solution, demonstrating that SiaC activates SiaD through a dynamic mechanism of promoting the formation of active SiaD dimers. Mutagenesis assay confirmed that the stalks of SiaD are necessary for its activation. Together, we reveal a novel mechanism for DGC activation, which clarifies the regulatory networks of c-di-GMP signaling.